Data on the biggest-selling vaccines helps us understand what's driving growth in the vaccines industry, and which companies are behind the wheel. Thanks in part to the adult influenza market and vaccines such as Gardasil and Prevnar, the global vaccines market has enjoyed a decidedly solid boost in revenue. Ten years ago, the vaccine market sat at $5.7 billion, according to Kalorama Information. Now, that market has soared to $27 billion.
Much of the growth comes as a result of a focus on flu prevention and an acceptance of adult vaccines. A few new vaccines joining the roster help, too. Sales of adult vaccines are expected to increase at a compound annual rate of 10.3% from 2010 to 2015, Kalorama reports.
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales.
Big Pharma products predictably dominated the list. Merck ($MRK) and GlaxoSmithKline ($GSK) take the cake when it comes to selling vaccines; each had 6 vaccines in the top 20 sales. Yet Sanofi ($SNY) and Pfizer ($PFE) had multiple products, too. And Novartis ($NVS) and Emergent BioSolutions each made an appearance.
With information provided by EvaluatePharma, the list is in. Take a look. -- Alison Bryant (email | Twitter)
|
H1 Sales: $1.847 billion |
|
|
H1 Sales: $672 million |
|
|
H1 Sales: $608 million |
|
|
H1 Sales: $535 million Company: GlaxoSmithKline Use: Diphtheria; Tetanus; Pertussis/whooping cough; Hepatitis B; Polio |
|
|
H1 Sales: $500 million Company: GlaxoSmithKline Use: Hepatitis A; Hepatitis B |
|
|
H1 Sales: $441 million Company: Novartis Use: Swine flu |
|
|
H1 Sales: $392 million Company: Merck & Co. Use: Varicella virus |
|
|
H1 Sales: $285 million Company: GlaxoSmithKline Use: HPV |
|
|
H1 Sales: $284 million Company: Merck & Co. Use: Rotaviral gastroenteritis |
|
|
H1 Sales: $274 million Company: GlaxoSmithKline Use: Pneumococcal infection; Otitis media |
|
|
H1 Sales: $266 million Company: GlaxoSmithKline Use: Rotaviral gastroenteritis |
|
|
H1 Sales: $224 million Company: Merck & Co. Use: Shingles; Herpes |
|
|
H1 Sales: $222 million Company: Pfizer Use: Pneumococcal infection; Otitis media |
|
|
H1 Sales: $219 million Company: Sanofi Use: Influenza |
|
|
H1 Sales: $217 million Company: Sanofi Use: Meningitis |
|
|
H1 Sales: $213 million Company: Merck & Co. Use: Pneumococcal infection |
|
|
H1 Sales: $207 million Company: Sanofi Use: Diphtheria; Pertussis/whooping cough; Tetanus |
|
|
H1 Sales: $180 million Company: Merck & Co. Use: Measles, Mumps, Rubella |
|
|
H1 Sales: $165 million Company: GlaxoSmithKline Use: Diphtheria; Tetanus; Pertussis/whooping cough |
|
|
H1 Sales: $88 million Company: Emergent BioSolutions Use: Anthrax |
|
Vaccine: Prevnar 13
Vaccine: PENTAct-HIB
Vaccine: Gardasil
Vaccine: Pediarix
Vaccine: Hepatitis Vaccine Franchise
Vaccine: Celtura
Vaccine: Varivax
Vaccine: Cervarix
Vaccine: RotaTeq
Vaccine: Synflorix
Vaccine: Rotarix
Vaccine: Zostavax
Vaccine: Prevnar
Vaccine: Fluzone/Vaxigrip
Vaccine: Menactra
Vaccine: Pneumovax
Vaccine: Adacel
Vaccine: MMR-II
Vaccine: Boostrix
Vaccine: Biothrax